Clinical Trial Update: A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease [Phase 3]

View source ↗

Summary

Phase 3b open-label trial assessing Rotigotine as an add-on to low-dose Pramipexole or Ropinirole in advanced Parkinson's disease completed, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Neupro (rotigotine)
• Pramipexole (pramipexole)
• Ropinirole (ropinirole)

Snippet

Sponsor: UCB BIOSCIENCES GmbH | Conditions: Advanced Parkinson's Disease | Phase 3 | Status: COMPLETED | Results posted: 2014-06-03